Dr. Lal Pathlabs Ltd.
Snapshot View

3691.60 -40.90 ▼-1.1%

30 July 2021, 10:08:00 A.M.
Volume: 3,790

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Hospital & Healthcare Services Compare with Industry peers
Website http://www.lalpathlabs.com
Financial Indicators
Market Cap 31,108.48 Cr.
Earnings per share (EPS) 34.99 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 106.67 Trailing Twelve Months Ending 2021-03
Industry PE 228.60 Trailing Twelve Months Ending 2021-03
Book Value / Share 144.61 Trailing Twelve Months Ending 2021-03
Price to Book Value 25.81 Calculated using Price: 3,732.50
Dividend Yield 0.54 Period Ending 2021-03
No. of Shares Subscribed 8.33 Cr. 83,344,877 Shares
FaceValue 10
Company Profile

The company was incorporated as ‘Dr. Lal PathLabs Private Limited’, a private limited company under the Companies Act, 1956, with a certificate of incorporation issued by the Registrar of Companies, National Capital Territory of Delhi and Haryana (RoC) on February 14, 1995 at Delhi. Subsequently, the name of the company was changed to ‘Dr. Lal PathLabs Limited’ upon conversion of the company into a public limited company pursuant to a special resolution of the shareholders of the company dated August 7, 2015 and a fresh certificate of incorporation was issued by the RoC on August 19, 2015. There has been no change in the registered office of the company since incorporation of the company.

The company focuses on providing patients quality diagnostic and related healthcare tests and services. The company’s focus on the patient as a customer is a critical differentiator in the diagnostic and healthcare industries and, together with what its brand’s recognition for quality diagnostic services, results in individuals and healthcare providers choosing it as their diagnostic healthcare service provider. This is because (i) in India, patients generally choose their diagnostic healthcare service provider and (ii) patients and healthcare providers seek quality healthcare service providers due to what range in quality and reliability of diagnostic healthcare services in India.

With over 3,368 diagnostic and related healthcare tests and services offered, the company is capable of performing substantially all of the diagnostic healthcare tests and services currently prescribed by physicians in India. Its diagnostic and related healthcare tests and services include (i) routine clinical laboratory tests - such as blood chemistry analyses and blood cell counts; (ii) specialized testing services - such as histopathology analyses, genetic marker-based tests, viral and bacterial cultures and infectious disease tests; and (iii) preventive testing services - such as screenings for hypertension, heart disease and diabetes. It performs these tests and services in its clinical laboratories using sophisticated and computerized instruments.

The company has built a national, “hub and spoke” network that includes its National Reference Laboratory in New Delhi. The company’s “hub and spoke” model, whereby specimens are collected across multiple locations within a region for delivery to a predesignated clinical laboratory for centralized diagnostic testing, provides greater economies of scale and offers a scalable platform for the continued growth of its business. Its network is present across India, including large cities such as New Delhi, Mumbai, Bengaluru, Chennai, Hyderabad and Kolkata. The company’s centralized information technology platform fully integrates its large network through a common logistics and payments system and tracks its operations and internal performance metrics, thereby enabling it to improve the efficiencies of its business.

Business area of the company

The company is a provider of diagnostic and related healthcare tests and services in India. Through its integrated, nationwide network, the company offers patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. Its customers include individual patients, hospitals and other healthcare providers and corporate customers.

Awards and accreditations

  • 2001: Received the ISO 9001:2008 certification for the quality management system for performance of routine and advanced diagnostic pathology testing services, including in clinical trials.
  • 2002: Fully accredited by the College of American Pathologists’ Laboratory Accreditation Program.
  • 2008: Awarded the CNBC TV18 Emerging India Award 2008 by ICICI Bank Business Banking in the pharmaceuticals and chemicals category.
  • 2010: Franchisor of the Year in healthcare, at the Franchise Plus Awards.
  • 2010: Honourable mention in the healthcare category at the Milagrow Trailblazers Brand Innovator Awards.
  • 2012: Diagnostic Service Provider Company of the Year, by Frost & Sullivan at the 4th Annual India Healthcare Excellence Awards.
  • 2012: Named a Computerworld Honours Laureate by the Computerworld Honours Program for innovative use of information technology to conduct research, develop new diagnostic methods and services and improve quality and access of patients to healthcare.
  • 2013: Best Diagnostic Company in India at the VC Circle Healthcare Summit.
  • 2014: Received the ISO 27001:2013 certification for the information management system for providing data center services and supporting functions.
  • 2014: Received an NABL certificate of accreditation under standard ISO 15189:2012 for “Medical Laboratories - Requirements for Quality and Competence” for medical testing, for National Reference Laboratory.
  • 2015: Data Quest Technology Award for Excellence in the implementation and use of technology for business benefits in the ‘Cloud’ category.
  • 2015: Received the certificate of affiliation from the Healthcare Sector Skill Council for role as medical laboratory technician in relation to institute at Gurgaon, Haryana, India.

Major events and milestones

  • 2005, 2007: Investment by WestBridge I Investments Holdings.
  • 2008: Acquisition of Paliwal Medicare and Paliwal Diagnostics.
  • 2010: Establishment of its National Reference Laboratory.
  • 2010, 2013: Investment pursuant to purchase of shares by Wagner Limited from WestBridge I Investment Holdings.
  • 2013: Investment pursuant to purchase of shares by WestBridge Crossover Fund, LLC from WestBridge I Investment Holdings.
  • 2013: Investment by SIH.
  • 2014: Acquisition of APL Clinical Institute of Clinical Laboratory & Research.
  • 2015: Amalgamation of Sanya Chemicals Private, Amolak Diagnostics, Medex Healthcare, Medicave Diagnostic Centre, Medicave Medical Systems and the company.
  • 2016: the Parent Company has set up new/acquired laboratories at various locations in India and some new patient service centers at various locations.
  • 2017: The Company had acquired 10% addiOonal equity stake in its exisOng two subsidiaries - Paliwal DiagnosOc Private Limited (PDPL) and Paliwal Medicave Private Limited (PMPL).
  • 2017: the Company has acquired 100% equity stake in “Delta Ria and Pathology Private Limited”, engaged in the business of providing pathological diagnosOcs services in Bhopal.
  • 2019: Company’s Wholly Owned Subsidiary viz M/s PathLabs Unifiers Private Limited acquired 70% equity stake in M/s Centrapath Labs Private Limited and M/s APRL PathLabs Private Limited consequent upon which both these Companies became subsidiaries of the Company.
  • 2019: The company acquired 70% equity stake in “APRL PathLabs Private Limited”, engaged in the business of providing pathological diagnostics services, on a going concern basis.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-1.10%
1 Week
+7.28%
1 Month
+12.81%
3 Month
+25.89%
6 Month
+64.26%
1 Year
+96.25%
2 Year
+241.06%
5 Year
+280.38%
9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 40.52 43.95 37.14 32.45 28.45 25.32 23.76 23.74 26.89
Return on Capital Employed (%) 57.93 60.49 48.87 47.43 43.07 37.90 34.78 32.94 36.03
Return on Assets (%) 25.86 27.30 24.67 25.06 24.13 21.81 20.38 18.81 19.87

Balance Sheet View Details

Particulars 9 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Shh. Funds 162 231 341 507 596 788 946 1,033 1,245
Non Curr. Liab. 3 1 -5 12 -6 -9 -20 70 83
Curr. Liab. 89 97 112 91 85 116 138 227 274
Minority Int. 2 2 2 3 2 4 5 21 31
Equity & Liab. 256 332 450 613 676 899 1,069 1,351 1,633
Non Curr. Assets 139 162 168 189 210 276 255 459 488
Curr. Assets 117 170 282 424 467 623 814 893 1,145
Misc. Exp. not W/O
Total Assets 256 332 450 613 676 899 1,069 1,351 1,633

Profit Loss View Details

Particulars 9 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Net Sales 452 558 660 791 912 1,057 1,203 1,330 1,581
Other Income 3 8 13 22 28 31 46 55 51
Total Income 455 566 673 813 940 1,088 1,249 1,385 1,633
Total Expenditure -354 -419 -504 -584 -675 -793 -910 -987 -1,145
PBIDT 101 147 168 229 265 295 340 399 488
Interest 0 0 0 -1 -1 -1 -1 -15 -16
Depreciation -20 -27 -28 -28 -28 -33 -38 -73 -77
Taxation -25 -39 -43 -67 -81 -90 -100 -83 -98
Exceptional Items
PAT 56 80 96 133 156 172 200 228 296

Cash Flow View Details

Particulars 9 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 88 98 122 159 171 197 219 284 398
Cash Fr. Inv. -65 -90 -113 -163 -137 -172 -100 -26 -212
Cash Fr. Finan. -15 -10 -1 0 -32 13 -55 -190 -139
Net Change 8 -2 8 -5 2 37 64 67 48
Cash & Cash Eqvt 17 16 23 19 29 66 129 197 244

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 56.91 56.91 56.81 56.77 56.32 55.23 55.23 55.23 55.23
Public 43.09 43.09 43.19 43.23 43.68 44.77 44.77 44.77 44.77
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Thu, 29 Jul 2021
Options Granted Under Dr. Lal Pathlabs Employee Restricted Stock Unit Plan.2016
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform you that Nomination & Remuneration Committee ("Committee") on Thursday July 29 2021 granted 750 (Seven Hundred and Fifty Only) Restricted Stock Unit options ("Options") under the Dr. Lal PathLabs Employee Restricted Stock Unit Plan 2016 ("RSU 2016"/ "Plan").
Thu, 29 Jul 2021
Proceedings Of The 27Th Annual General Meeting Of The Company
We wish to inform you that the 27th Annual General Meeting ("AGM") of the Company was held today i.e. Thursday July 29 2021 at 10.30 A.M. (IST) through Video Conference in compliance with the provisions of Companies Act 2013 & circulars issued by Ministry of Corporate Affairs.

In this regard please find enclosed proceedings of the AGM
Thu, 29 Jul 2021
Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations 2015)
Dr. Lal PathLabs Ltd has informed BSE regarding the details of Voting results of AGM under Regulation 44(3) of SEBI (LODR) Regulations 2015. Kindly Click here

Technical Scans View Details

Thu, 29 Jul 2021
Stock Outperforming Benchmark Index in both 1 Week and 3 Month Stock Outperforming Benchmark Index in both 1 Week and 3 Month
Stock Outperforming Sectoral Index in both 1 Week and 3 Month Stock Outperforming Sectoral Index in both 1 Week and 3 Month
Strongly Outperforming Benchmark Index Strongly Outperforming Benchmark Index
Strongly Outperforming Sectoral Index Strongly Outperforming Sectoral Index
Increasing Relative Strength - Sectoral Index Increasing Relative Strength - Sectoral Index

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 168,733.23 709.85 +0.9%
Divi's Laboratories Ltd. 128,656.69 4,875.00 +0.6%
Dr. Reddy's Laboratories Ltd. 77,707.65 4,738.35 +1.4%
Cipla Ltd. 71,170.06 881.90 0.0%
Cadila Healthcare Ltd. 58,547.84 578.95 +1.2%
Apollo Hospitals Enterprise Ltd. 58,067.43 4,064.85 +0.6%
Aurobindo Pharma Ltd. 53,214.94 911.25 +0.3%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 58.11 709.85 +0.9%
Divi's Laboratories Ltd. Consolidated 2021-03 64.84 4,875.00 +0.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 44.73 4,738.35 +1.4%
Cipla Ltd. Consolidated 2021-03 29.59 881.90 0.0%
Cadila Healthcare Ltd. Consolidated 2021-03 27.44 578.95 +1.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 386.19 4,064.85 +0.6%
Aurobindo Pharma Ltd. Consolidated 2021-03 9.98 911.25 +0.3%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.63 709.85 +0.9%
Divi's Laboratories Ltd. Consolidated 2021-03 13.84 4,875.00 +0.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.35 4,738.35 +1.4%
Cipla Ltd. Consolidated 2021-03 3.88 881.90 0.0%
Cadila Healthcare Ltd. Consolidated 2021-03 4.51 578.95 +1.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.64 4,064.85 +0.6%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.43 911.25 +0.3%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 709.85 +0.9%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,875.00 +0.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,738.35 +1.4%
Cipla Ltd. Consolidated 2020-03 0.18 881.90 0.0%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 578.95 +1.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,064.85 +0.6%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 911.25 +0.3%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 709.85 +0.9%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,875.00 +0.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,738.35 +1.4%
Cipla Ltd. Consolidated 2020-03 10.09 881.90 0.0%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 578.95 +1.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,064.85 +0.6%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 911.25 +0.3%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 709.85 +0.9%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,875.00 +0.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,738.35 +1.4%
Cipla Ltd. Consolidated 2020-03 12.53 881.90 0.0%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 578.95 +1.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,064.85 +0.6%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 911.25 +0.3%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 709.85 +0.9%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,875.00 +0.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,738.35 +1.4%
Cipla Ltd. Consolidated 2020-03 17,131.99 881.90 0.0%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 578.95 +1.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,064.85 +0.6%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 911.25 +0.3%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 709.85 +0.9%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,875.00 +0.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,738.35 +1.4%
Cipla Ltd. Consolidated 2020-03 1,546.98 881.90 0.0%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 578.95 +1.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,064.85 +0.6%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 911.25 +0.3%